Rockwell Medical, Inc.
Methods of Reducing Doses of Erythropoietin Stimulating Agents in Hyporesponsive Patients

Abstract:

The invention provides for methods of treating a dialysis patient that is hyporesponsive to erythropoietin stimulating agents (ESA) comprising administering soluble ferric triphosphate (SFP) composition and administering a dose of ESA that is significantly reduced compared to the dose of ESA required by a dialysis patient that is hyporesponsive to ESA that has not received SFP.